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Background: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are renoprotective but
both may increase serum potassium concentrations in patients with chronic kidney disease (CKD). The proportion
of affected patients, the optimum follow-up period and whether there are differences between drugs in the
development of this complication remain to be ascertained.
Methods: In a randomized, double-blind, phase IV, controlled, crossover study we recruited 30 patients with stage
3 CKD under restrictive eligibility criteria and strict dietary control. With the exception of withdrawals, each patient
was treated with olmesartan and enalapril separately for 3 months each, with a 1-week wash-out period between
treatments. Patients were clinically assessed on 10 occasions via measurements of serum and urine samples. We
used the Cochran–Mantel–Haenszel statistics for comparison of categorical data between groups. Comparisons
were also made using independent two-sample t-tests and Welch’s t-test. Analysis of variance (ANOVA) was
performed when necessary. We used either a Mann–Whitney or Kruskal-Wallis test if the distribution was not
normal or the variance not homogeneous.
Results: Enalapril and olmesartan increased serum potassium levels similarly (0.3 mmol/L and 0.24 mmol/L
respectively). The percentage of patients presenting hyperkalemia higher than 5 mmol/L did not differ between
treatments: 37% for olmesartan and 40% for enalapril. The mean e-GFR ranged 46.3 to 48.59 ml/mint/1.73 m2 in
those treated with olmesartan and 46.8 to 48.3 ml/mint/1.73 m2 in those with enalapril and remained unchanged
at the end of the study. The decreases in microalbuminuria were also similar (23% in olmesartan and 29% in
enalapril patients) in the 4 weeks time point. The percentage of patients presenting hyperkalemia, even after a two
month period, did not differ between treatments. There were no appreciable changes in sodium and potassium
urinary excretion.
Conclusions: Disturbances in potassium balance upon treatment with either olmesartan or enalapril are frequent
and without differences between groups. The follow-up of these patients should include control of potassium
levels, at least after the first week and the first and second month after initiating treatment.
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The rate of raised serum potassium concentration in hos-
pitalized patients and in admissions to emergency depart-
ments is high and may represent an ominous marker of
increased risk of death [1]. This is more common among
patients with impaired renal function and defects in the
excretion of renal potassium, with some associated clinical
conditions and treatment with a growing list of drugs
[2-7]. Although there is considerable inter-individual vari-
ation in susceptibility, hyperkalemia may be responsible
for alterations in the excitatory capacity of the heart con-
duction system and is consequently associated with severe
arrhythmogenesis and fatal consequences [8,9].
The incidence of hyperkalemia is quite low in patients
with normal renal function: >2% but increases from 2% to
42% as the GFR diminishes to 20 ml/min 1.73/m2 [10].
There are multiple triggering factors in chronic kidney
disease (CKD) patients, but a significant proportion of epi-
sodes of hyperkalemia are attributed to the use of drugs
taken to alleviate concomitant hypertension, especially
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) as they inhibit the
renin-angiotensin system and cause a reduction in serum
aldosterone [11]. It has been also described that hy-
perkalemia develops in approximately 10 percent of out-
patients within a year of ACEIs being prescribed [12].
Furthermore, in six separate clinical trials of more than
1500 people with CKD, increased levels of 0.3-0.6 mmol/L
were detected in the ACEI randomized patients [7]. This
increase in serum potassium led to discontinuation of
ACEI therapy in 1.2 to 1.6% of patients in any given trial.
Both ACEIs and ARBs are widely included in clinical
guidelines to manage hypertension and other risk factors
associated with the course of atherosclerosis [13-15] and
may significantly delay the progression of renal damage
in patients with chronic kidney disease [16-21]. There-
fore, nephrologists face a paradoxical and clinically sig-
nificant challenge in this realm because those patients
who would benefit most from treatment with ACEIs or
ARBs are precisely those with the highest risk of adverse
effects. In addition, in these patients any prediction of
potentially dangerous potassium disturbances is compli-
cated by the consequences of a non-controlled diet, con-
comitant drugs and other associated chronic diseases.
Consequently, safety issues regarding the use of these
drugs in patients with renal insufficiency and in those
with moderate CKD are not yet completely established
[22,23]. The real incidence of hyperkalemia as a result of
these treatment regimes is not well known because avail-
able evidence is difficult to interpret due to the influence
of confounding factors [24-26], which is particularly evi-
dent in patients with CKD [27]. Despite the lack of clear
evidence some authors have stated that the increase in
serum potassium is less pronounced during therapy withARBs and that the risk of hyperkalemia is higher in
patients treated with ACEIs [7,23].
Data supporting potential differences between ACE in-
hibitors and ARBs in serum potassium concentrations
come from clinical trials that compare the effect of an
ACEI to an ARB on renal function in people with heart
failure. These trials demonstrated a lower incidence of
hyperkalemia in patients randomly assigned to an ARB
treatment compared with those randomized to ACEI treat-
ment. In these studies there was a similar proportion of
patients with CKD but they were receiving, at the same
time, not only other different potassium-influencing drugs
(diuretics, betablockers or potassium supplements) [24,28],
but at different and non-specified doses.
We believe to demonstrate that one drug or another
produces more or less hyperkalemia it is indispensable
that this be the only potassium-influencing medication
utilized. So currently there is little clear evidence for as-
suming differences between equipotent doses of ARB
and ACEI to cause hyperkalemia.
Hence, our study is designed in this way, so that the
only potassium-influencing drugs which our patients re-
ceived were those permitted in the trial. All our patients
had the same level of CKD and they followed a stan-
dardized potassium diet.
Bearing in mind the large amount of patients indicated
to receive ACEIs or ARBs, the risk of associated CKD
(heart failure, advanced age, etc.), as well as the risk of
hyperkalemia, we believed that it would be of great inter-
est to learn whether one of these medications produce less
hyperkalemia than the other.
In this study we challenge this assumption by assessing
the effect of standard-of-care treatment with olmesartan
and enalapril, as representatives of ARBs and ACEIs re-
spectively, on the incidence of hyperkalemia in patients
with stage 3 CKD.
Methods
It was designed as a randomized, double-blind, phase IV,
controlled, crossover study.
Among patients attending our outpatient clinic for
management of CKD in a tertiary care teaching hospital,
patients with stage 3 CKD, i.e. estimated GFR (eGFR)
between 30 and 60 ml/min/1.73 m2, stable clinical con-
dition, aged 18–75 years, serum potassium concentra-
tion <5 mmol/L and blood pressure (BP) ranging
between 130/80 mmHg and 180/100 mmHg, were con-
sidered for inclusion (n = 120). The use of calcium
channel blockers or alpha-adrenergic blockers was not
an exclusion criterion. For enrollment, strict exclusion
criteria were established to exclude the presence of
confounding factors that could alter the incidence of
potassium disturbances during the treatment period as
outlined in Table 1. No patient with a known arterial
Table 1 Criteria for exclusion reported during the enrollment period
Declined to participate (n = 26) Secondary arterial hypertension (n = 5)
Previous allergic reaction to ACEIs (n = 3) Previous allergic reaction to ARBs (n = 2)
Active disease in other organs (n = 6) Previous gastrointestinal surgery (n = 1)
Diseases causing malabsorption (n = 1) Recent (1 year) ischemic episodes (n = 9)
History of ventricular arrhythmias (n = 2) History of cardiac insufficiency (n = 8)
Current prescription with diuretics (n = 9) Current prescription with potassium (n = 4)
Current prescription with B-blockers (n = 7) Current prescription with NSAIDs (n = 3)
ACEIs: Angiotensin-converting enzyme inhibitors, ARBs: Angiotensin receptor blockers, NSAIDs: nonsteroidal anti-inflammatory drugs, B-blockers: Beta-blockers.
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identified 34 eligible patients, 4 of whom were discarded
during the screening visits due to failure to follow a bal-
anced diet that was relatively low in sodium and
contained 80–90 mmol/day of potassium as assessed via
repeated measurement of electrolytes in 24-h urine
samples. To fulfill restrictive eligibility criteria and strict
dietary control patients were also instructed not to in-
gest salt substitutes or herbs. Finally we recruited 30 pa-
tients with stage 3 CKD who were informed about the
trial and invited to participate and sign the informed
consent approved by our institutional review board. Pa-
tients received olmesartan and enalapril sequentially,
(Figure 1) and we chose the two-period design for sim-
plicity. Raised serum potassium levels and lack of adher-
ence were defined as reasons for withdrawal.
This number was considered sufficient according to
available data [23] and assuming a difference between
groups exceeding 10%, an overall standard deviation of
20% and 80% power with a two-sided 5% significance level.
We anticipated that dropouts and withdrawals would not
influence the primary outcome, i.e. the proportion of pa-
tients in whom hyperkalemia was detected. We then
proceeded according to Figure 1. Enrolled patients (20
men and 10 women) were born in our geographic area
and all of them were Caucasian. There were no differences
in age, BMI or other relevant variables (Table 2). Thus pa-
tients received olmesartan and enalapril sequentially in a
controlled crossover, longitudinal design (Figure 1). We
considered hyperkalemia as potassium level of 5.0 mmol/L
or higher [10,29].
We withdrew ACEIs, ARABs, betablockers, diuretics
and any drug which could influence potassium levels
15 days before performing the baseline analyses. After that
we randomized the patients to receive either: 10 mg of
olmesartan or 10 mg of enalapril for one week, after which
we performed an analytic determination. At that point pa-
tients with potassium levels <5 mmol/L were instructed to
increase the dose to 20 mg/day in week 3, with an analytic
control at week 4. Following, that controls were performed
at weeks 8 and 12. Once this phase was finished and after
a 7–10 day wash-out period, the patients were prescribed
the alternative drug and repeated this itinerary for threemonths more. Any patient with potassium >5 mmol/L
was withdrawn from the trial. Those patients withdrawn
from the first phase underwent a 7–10 day wash-out
period and, after ensuring their potassium levels were nor-
mal, were then transferred to the second phase.
Each patient was visited 10 times throughout the study
for reinforcement and to avoid severe complications.
Health care providers and participants were blinded to the
drug assignment. The members of staff responsible for the
intervention were instructed to temporarily stop the medi-
cation if hyperkalemia, changes in renal function or lack of
adherence to the diet were detected. This was achieved
with the independent contribution of pharmacists who
were also responsible for dispensing the drugs in num-
bered bottles to conceal the allocation sequence, simple
randomization using a computerized random number gen-
erator and storage of the allocation list. These procedures
resulted in unbalanced allocation (n = 17 for olmesartan
and n = 13 for enalapril). After the wash-out period at the
crossover stage, some patients refused to continue the
study, alleging the requirement for excessive commitment.
Secondary measurement outcomes included potentially af-
fected variables. Blood pressure and eGFR were measured
as described elsewhere [13,30]. Adherence to medication
and diet was assessed using the Morisky-Green test and
the brief medication questionnaire [31,32]. Whilst no data
is available comparing equipotent doses of olmesartan (half
life 12 hours) with enalapril (half life 11 hours), there are
other studies comparing 5 mg of ramipril with 20 mg of
enalapril or 5 mg of ramipril with 20 mg de olmesartan,
meaning that these doses of enalapril and olmesartan could
be considered comparable [33,34].
Routine analyses at each visit included creatinine, po-
tassium, sodium and osmolarity in serum and albumin
(microalbuminuria), creatinine, sodium and potassium
in urine. At the beginning and the end of two periods of
treatment (visits 1, 5, 6 and 10), plasma renin activity
and aldosterone were also measured. The trial was
according to the Helsinki declaration and was authorized
by the local ethics committee and by the Spanish Agency
for Medicines and Medical Products (AGEMED) which
provided support and authorized the trial EudraCT
“2008-002191-98”.
Figure 1 Flow diagram of participants through each stage of the trial indicating for each group the number of participants assigned
that received intended treatment and were analyzed for the primary outcome.
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procedures using automatic analyzers. Allocation con-
cealment was extended to the laboratory personnel. Un-
less otherwise stated, variables are expressed as mean
and standard error of the mean. We used the Cochran–
Mantel–Haenszel statistics for comparison of categor-
ical data between groups, particularly the proportion of
patients with hyperkalemia. Comparisons were also
made using independent two-sample t-tests, in some
cases with unequal sample sizes and unequal variance
(Welch’s t-test). To avoid multiple two-sample t-tests and
the increased chance of committing a type I error, analysis
of variance (ANOVA) was performed when necessary. We
used either a Mann–Whitney or Kruskal-Wallis test if the
distribution was not normal or the variance was not
homogeneous. A two-tailed P < 0.05 was considered statis-
tically significant. Individual missing data were notimputed in an expectation-maximization algorithm. Statis-
tical analyses were performed using the Statistical Package
for the Social Sciences, version 18.0 (SPSS Inc., Chicago,
Il, USA).
Results
During the first period, 38% of patients receiving enalapril
developed hyperkalemia, all during the first week.
Hyperkalemia in the olmesartan group was detected in
41% of patients at different time-points (weeks 1 (n = 3), 4
(n = 3) and 8 (n = 1)). At the end of the first period, 13 pa-
tients declined to continue for various reasons, confirming
the high rate of attrition in studies with designs that re-
quire strong commitment, continuous control of diet and
other confounding factors. We considered that 7–10 days
of wash out was adequate because potassium and aldoster-
one levels in all patients had returned to their basal before
Table 2 Participants’ characteristics and values for
selected variables before the first allocation
Olmesartan Enalapril P-
value(n = 17) (n = 13)
Age, years 60.2 (12.9) 59.9 (11.6) NS
Female, n (%) 8 (47.1) 2 (15.4) <0.0001
BMI, kg/m2 27.7 (6.2) 27.41 (4.1) NS
Systolic blood pressure, mm Hg 134.8 (4.2) 140.1 (4.2) NS
Diastolic blood pressure, mm Hg 78.7 (1.7) 76.2 (1.8) NS
Dyslipidaemia, n (%) 6 (35.3) 5 (38.5) NS
Serum creatinine, mg/dl 1.65 (0.07) 1.60 (0.06) NS
Glomerular filtration rate,
ml/min/1.73 m2
42.24 (2.0) 46.2 (1.9) NS
Plasma renin activity, ng/ml/h 1.13 (1.12) 1.30 (1.46) NS
Plasma aldosterone, ng/dl 30.6 (4.0) 27.1 (5.5) NS
Diabetic patients, n (%) 1 (5,8) 2(15) NS
BMI: Body mass index, NS: no significant.
Values are expressed as mean ± SE of the mean.
Figure 2 The increase in serum potassium concentration during
the first week of treatment was significant and similar for enalapril
(n = 20) and olmesartan (n = 27). (A) The effects of both drugs in
microalbuminuria (B) and glomerular filtration rate (C) during the trial
were also similar between groups. Valid results for e-GFR were obtained
for enalapril: n = 22,16,14,14 and for olmesartan: n = 24,24,16,11 for
measurements at t = 0, 1, 4, 8 and 12 weeks, respectively. Valid results for
microalbuminuria were obtained for enalapril: n = 17,14,10,10 and for
olmesartan: n = 24,22,14,12 for measurements at t = 0, 1, 4, 8 and
12 weeks, respectively. *p < 0.05.
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42% of patients in the enalapril group developed
hyperkalemia, and thus were withdrawn from the study at
weeks 4 (n = 1) and 8 (n = 2). A similar percentage of those
treated with olmesartan also developed kyperkalemia at
the same time-points. Therefore, 27 patients fully partici-
pated in the olmesartan arm and 20 in the enalapril arm,
resulting in unbalanced groups that prevented inferences
with respect to secondary outcomes and further analysis
of association between the presence of hyperkalemia and
other measured variables. Mild adverse effects were
reported in both groups, n = 16 for olmesartan and n = 10
for enalapril. We had two diabetic patients in the enalapril
group and one in the olmesartan group (Table 2). One out
of three of the diabetic patients included in the study
showed raised potassium levels with both drugs. Two pa-
tients showed hyperkalemia with olmesartan and not with
enalapril and likewise 2 patients showed hyperkalemia
with enalapril and not with olmesartan.
Of note, there was no significant increase in serum po-
tassium with either olmesartan or enalapril in 50% of
patients. There were no significant differences in the per-
centage of patients with hyperkalemia with respect to the
treatment group (37% for olmesartan and 40% for enala-
pril). However, there was a significant (p < 0.05) and im-
mediate (1 week) increase in serum potassium levels with
respect to baseline values in both treatments; 10.5% for
olmesartan (from 4.35 ± 0.05 to 4.59 ± 0.05 mmol/L)
and 10.7% for enalapril (from 4.30 ± 0.06 to 4.60 ±
0.09 mmol/L) (Figure 2). This trend only remained signifi-
cant during the first 8 weeks. Olmesartan patients showed
potassium levels of up to 5.1 mmol/L: 2 patients in week
1, up to 6.5 mmol/L: 2 patients in week 4 and up to
5.1 mmol/L: 1 patient in week 8. Patients treated withenalapril showed potassium levels of up to 5.5 mmol/L: 1
patient in week 1, up to 5.4 mmol/L: 1 patient in week 4
and up to 5.2 mmol/L: 2 patients in week 8.
That is to say, up to week 8, 3 out of 30 (10%) patients
who were treated with these drugs did not show potas-
sium levels over 5 mmol/L. Only two patients, one in
each treatment group, reached potassium levels above
5.5 mmol/L, and the highest figure was 6,4 mmol/L in a
diabetic patient.
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of 135.78 ±16 mmHg and of 124 ±13 mmHg at the end
p < 0.05, baseline diastolic BP was 79.7 ± 6.8 mmHg and
74 ±10 mmHg at the end p = 0.09. In olmesartan treated
patients baseline systolic BP was 136.33 ± 17.9 mmHg
and 131.13 ± 13 mmHg at the end p = 0.4, diastolic
baseline BP was 79 ± 7 mmHg and 78 ± 9 at the end
p = 0.7. It is true that the drop in systolic BP was signifi-
cant in enalapril patients with regards to baseline, how-
ever the differences were not significative when we
compared the systolic and diastolic BP at baseline be-
tween olmesartan and enalapril patients and systolic
and diastolic BP at the end of the study.
In that sense we should say that our objective was not
BP control but to maintain the ACEI/ARB doses in order
to perform strict evaluation of potassium levels. The pa-
tients were receiving different doses of doxazosine or
calcium-channel-blockers at baseline and in many cases
their BP was already treated and controlled before begin-
ning the trial. If the patient required a drug to lower BP
we did this with different doses of doxazosine or calcium-
channel-blockers. Therefore, we believe that it is not pos-
sible to draw conclusions on BP evolution.
Furthermore, among those terminating the study there
were no significant differences in urinary potassium with
respect to baseline values (79.6 ± 9.4 vs. 81.1 ± 8.1 mmol/L
for olmesartan and 81.7 ± 15.2 vs. 62.7 ± 6.5 mmol/L for
enalapril) or appreciable changes in daily urine sodium
elimination. Similar trends were observed for the
transtubular potassium gradient (6.7 ± 0.4 vs. 6.75 ± 0.5 for
olmesartan and 6.8 ± 0.6 vs. 6.21 ± 0.7 for enalapril). The
baseline serum osmolarity was within normal levels. At
12 weeks we observed a trend towards higher plasma
renin activity in both arms that did not reach statistical
significance (1.13 ± 1.12 vs. 1.56 ± 1.77 and 1.30 ± 1.46 vs.
1.61 ± 1.83 ng/ml/h for olmesartan and enalapril respect-
ively) and lower plasma aldosterone that was only signifi-
cant (p < 0.05) for enalapril (27.6 ± 3.8 vs. 18.7 ± 2.9 ng/dl).
Microalbuminuria, which was tested as a urine spot: mg
albumin/gr creatinine ratio, was 278 ± 134 and 151 ± 119
at baseline for olmesartan and enalapril patients respect-
ively, which had diminished to 213 ± 90 and 106 ± 59 re-
spectively (Figure 2) at the end of the 4th week. That
represents an overall decrease in microalbuminuria con-
centrations of 23% and 29% for the olmesartan and enala-
pril groups respectively. This decrease only reached
statistical significance when compared with ANOVA indi-
cating a detectable trend towards a positive effect. We
found no further decrease of microalbuminuria in the fol-
lowing controls (Figure 2).
Finally, baseline eGFR of olmesartan patients went from
46.3 ± 3.7 to 48.59 ± 4.3 ml/mint/1.73 m2 at the end, and
the baseline eGFR of enalapril patients went from 46.8 ±
3.1 to 48.3 ± 4.3 ml/mint/1.73 m2 at the end. The e-GFRunderwent a slight decrease in the first weeks, recovering
at the end of the study (Figure 2).
Discussion
Sudden cardiac arrest and arrhythmia are prominent
causes of death among patients with chronic kidney dis-
ease and in most cases the patient’s potassium level is as-
sociated with the risk of death [35]. Therefore, it is
clinically advisable to carefully monitor these patients, to
ensure proper dietary management and to avoid poten-
tially deleterious drugs. According to our data, in this
CKD stage 3 group, olmesartan and enalapril increased
potassium levels at a mean of 0.3 mmol/L, which was
greater than 5 mmol/L in 40% of patients. The clinical im-
plications are relevant because potassium levels require
continuous surveillance and because these drugs are ef-
fective in retarding the progression of renal disease, espe-
cially when this is moderate and requires strict control of
blood pressure [36]. A possible clinical difference between
ACEIs and ARBs in terms of their effect on serum potas-
sium was initially described [7,24,28], but modifications to
drugs in these categories are continuously being incorpo-
rated into the therapeutic armamentarium, with possible,
unexplored effects. A common problem is that trials do
not appreciate the effect of stringent criteria for with-
drawal and the strict control of confounding factors
[8,12,16]. There has been no previous clinical study com-
paring olmesartan and enalapril in stage 3 CKD patients.
We continuously controlled sodium and potassium intake
and excretion in order to limit possible changes in serum
potassium levels to those due to the presence of the drugs
assayed. We found no significant differences between
olmesartan and enalapril in their capacity to cause
hyperkalemia in patients with e-GFR >30 and <60 ml/
min/1.73 m2 but confirmed that both drugs influence the
potassium balance [7,26], decrease urinary albumin excre-
tion by 25% at 1 month and maintain renal function. Add-
itionally, we found that we should not expect changes in
serum potassium levels due to these drugs in approxi-
mately half of patients with CKD in whom diet is con-
trolled. As previously suggested this may be partially
attributed to the unequal distribution of polymorphisms
in the angiotensin-converting enzyme gene [37].
Differences between ACEIs and ARBs, however, were
initially plausible considering their differential effect on
the bradikinine metabolism and plasmatic renal flow
[22,23]. Our findings of lower plasma aldosterone and
greater anti-hypertensive effects with enalapril provide fur-
ther support for such differences. There were no differen-
tial effects on serum potassium level in uncontrolled
patients with normal renal function, as demonstrated in a
comparison between lisinopril and candesartan [38]. Only
one study exists, also well designed, which compared
80 mg of Valsartan with 10 mg of lisinopril in 18 stage 3
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hyperkalemia. The explanation could lie in the different
half lives of these drugs (12 hours for lisinopril and 6 hours
for valsartan) [39], which could mean valsartan had less ef-
fect on potassium levels. In this study there is no reference
to the potassium intake [7].
There are no data to support a difference in potency be-
tween olmesartan and enalapril; they have similar half lives
(11 hours for enalapril and 12 hours for olmesartan) [39]
and animal models indicate that olmesartan and enalapril
are equivalent [40]. Moreover, studies comparing ACEIs
and ARBs have yielded similar results [36,41]. No differ-
ences have been reported between ACEIs [42], but
olmesartan has been reported as the most potent ARB to
date [43,44].
We were particularly careful to avoid differences in
dietary potassium intake. We are aware that assessment
may be biased by the type of ingestion and the methods
of recall [45] and consequently we included continuous
laboratory measurement of electrolyte balance. Lack of
adherence was limited but caused some withdrawals.
The intake of potassium in a free-diet varies between 42
and 270 mmol/day. Our restrictions resulted in similar
individual daily urinary potassium and sodium excretion
and no relevant differences between drugs, supporting
our conclusion that 20 mg of olmesartan does not pro-
duce more hyperkalemia than 20 mg of enalapril in stage
3 CKD patients. It is difficult to know if these results
can be attributed to the entire pharmacological class or
specifically to these two drugs.
In fact both drugs increased serum potassium levels.
This increase was not particularly high due to our selec-
tion criteria and exhaustive control but values higher than
5 mmol/L were found in 30–40% of patients studied, indi-
cating a frequent concern at this stage that is probably
more important in patients with more severe CKD and in
patients with dual blockade of the renin-angiotensin sys-
tem [4]. Clinicians should consider that in daily clinical
practice, in the “real world”, patients are usually influenced
by a free potassium diet and established or temporary con-
ditions that may aggravate hyperkalemia. Hence the effect
of prescribed drugs should be monitored frequently. If
treatment is not readily withdrawn, as described previ-
ously [12], the incidence of severe hyperkalemia may in-
crease, notably within the first year of treatment. This is
particularly relevant as severe hyperkalemia is found in 1%
of ambulatory patients and most with suboptimal follow-
up and management; very moderate increases in serum
potassium may also generate arrhythmia [10,46]. We also
wish to underline that having “slightly” and sustained,
higher levels of potassium, not affecting the electrical car-
diac conduction, could cause other unknown effects in the
long term. On the other hand, we believe that these drugs
should be utilized when indicated, if well managed(diuretics, diet, etc.) to maintain adequate potassium
levels. Bearing in mind that some patients showed
hyperkalemia with one drug and not with the other, we
believe that in those patients with indispensable indica-
tion, for example, heavy proteinuria, we could try the al-
ternative drug.
It is well documented that CKD patients in whom treat-
ment with ACEIs or ABRs is indicated should be fre-
quently checked for serum potassium levels. The most
usual recommendations indicate that this should be done
7–10 days after prescription [10].
Nevertheless, in the light of our results we believe that
stage 3 CKD patients treated with these drugs should also
be controlled at the end of month 1 and 2; After that point,
patients should be controlled at the periods recommended
at guidelines, to follow-up stable stage 3 CKD patients, and
also when a concomitant disease appears. Whether this is a
cost-effective recommendation remains to be ascertained.
Conclusions
In conclusion, patients with stage 3 CKD are prone to dis-
turbances in potassium balance upon treatment with
either olmesartan or enalapril. Hyperkalemia was present
in a significant number of patients and there were no rele-
vant differences between drugs. The follow-up of these
patients should include frequent measurement of potas-
sium levels at least during the first 2 months of treatment.
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